Vivozon Pharmaceutical (A082800) Stock Overview
Researches, develops, produces, and sells LED products primarily in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A082800 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Vivozon Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,450.00 |
| 52 Week High | ₩13,600.00 |
| 52 Week Low | ₩4,540.00 |
| Beta | -0.74 |
| 1 Month Change | -9.18% |
| 3 Month Change | -38.11% |
| 1 Year Change | -28.23% |
| 3 Year Change | 28.61% |
| 5 Year Change | -59.91% |
| Change since IPO | -92.09% |
Recent News & Updates
Some Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:082800) Shareholders Look For Exit As Shares Take 35% Pounding
Oct 14
Is Vivozon Pharmaceutical (KOSDAQ:082800) Using Too Much Debt?
Sep 08Recent updates
Some Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:082800) Shareholders Look For Exit As Shares Take 35% Pounding
Oct 14Is Vivozon Pharmaceutical (KOSDAQ:082800) Using Too Much Debt?
Sep 08Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) Business Is Trailing The Industry But Its Shares Aren't
Jun 17Vivozon Pharmaceutical (KOSDAQ:082800) Takes On Some Risk With Its Use Of Debt
Mar 12More Unpleasant Surprises Could Be In Store For Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) Shares After Tumbling 25%
Mar 12Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) Shares Climb 40% But Its Business Is Yet to Catch Up
Dec 12We Think Vivozon Pharmaceutical (KOSDAQ:082800) Is Taking Some Risk With Its Debt
Dec 02Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) Shares Climb 35% But Its Business Is Yet to Catch Up
Oct 28What Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) 33% Share Price Gain Is Not Telling You
Aug 02Vivozon Pharmaceutical (KOSDAQ:082800) Has A Somewhat Strained Balance Sheet
Jul 29Some Shareholders Feeling Restless Over Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) P/S Ratio
Jun 04We Think Vivozon Pharmaceutical (KOSDAQ:082800) Has A Fair Chunk Of Debt
Mar 23Is Vivozon Healthcare (KOSDAQ:082800) A Risky Investment?
May 06Estimating The Intrinsic Value Of Vivozon Healthcare, Inc. (KOSDAQ:082800)
Feb 18Did You Miss Vivozon Healthcare's (KOSDAQ:082800) Impressive 116% Share Price Gain?
Dec 04Shareholder Returns
| A082800 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -11.7% | 5.4% | 1.6% |
| 1Y | -28.2% | 27.6% | 61.8% |
Return vs Industry: A082800 underperformed the KR Pharmaceuticals industry which returned 27.6% over the past year.
Return vs Market: A082800 underperformed the KR Market which returned 61.8% over the past year.
Price Volatility
| A082800 volatility | |
|---|---|
| A082800 Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 10.8% |
| 10% least volatile stocks in KR Market | 2.5% |
Stable Share Price: A082800's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A082800's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 303 | Jin Lee | www.lumimicro.com |
Vivozon Pharmaceutical Co., Ltd. researches, develops, produces, and sells LED products primarily in South Korea. The company offers LED packages for interior, general, indoor, decorative, and automotive lighting, as well as display applications. It also provides LED set linear lamps, including panel lamps, down lights, and flood lights for residential, commercial, and industrial structures, as well as lights for parking lots.
Vivozon Pharmaceutical Co., Ltd. Fundamentals Summary
| A082800 fundamental statistics | |
|---|---|
| Market cap | ₩225.20b |
| Earnings (TTM) | -₩28.56b |
| Revenue (TTM) | ₩66.40b |
Is A082800 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A082800 income statement (TTM) | |
|---|---|
| Revenue | ₩66.40b |
| Cost of Revenue | ₩36.45b |
| Gross Profit | ₩29.95b |
| Other Expenses | ₩58.51b |
| Earnings | -₩28.56b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -576.41 |
| Gross Margin | 45.11% |
| Net Profit Margin | -43.02% |
| Debt/Equity Ratio | 43.2% |
How did A082800 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/17 15:54 |
| End of Day Share Price | 2025/11/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vivozon Pharmaceutical Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyun Yong Kim | SK Securities Co., Ltd. |